Extended follow-up from the DREAMM-2 trial
The potential of belantamab mafodotin (belamaf) in the relapsed or refractory (R/R) multiple myeloma (MM) setting was highlighted in 2019, when the pivotal DREAMM-2 study met its primary endpoint.
The potential of belantamab mafodotin (belamaf) in the relapsed or refractory (R/R) multiple myeloma (MM) setting was highlighted in 2019, when the pivotal DREAMM-2 study met its primary endpoint.
During the EHA-EBMT 6th European CAR T-cell Meeting, the Multiple Myeloma Hub spoke to Paola Neri, University of Calgary, Calgary, CA. We asked, What factors…
Here, we summarize a report published by Guerrero et al. in Blood on predictors of unsustainable MRD-negativity in patients with multiple myeloma who are eligible…
Here, we summarize a retrospective study published by Lery et al. in Journal of the American Academy of Dermatology on the dermatological toxicities associated with…
On March 20, 2024, the European Commission granted approval to ide-cel for the treatment of triple-class-exposed RRMM with two or more prior therapies, including an…
Here, we summarize a study published by Nieto et al. in American Journal of Hematology on the safety and efficacy of high-dose panobinostat combined with…
The supplemental Biologics License Application for Abecma in this indication remains under review with the FDA; Abecma has been approved in Japan and Switzerland and…
Here, we summarize a post hoc analysis investigating the effects of refractoriness to standard-dose prior alkylators on the effectiveness of melflufen + dexamethasone on a…
We summarize key results from the phase II GMMG-CONCEPT trial investigating transplant-eligible and non-transplant-eligible patients with newly diagnosed high-risk multiple myeloma treated with isatuximab, carfilzomib,…
Current and Future Perspectives for Bispecific Antibodies in Multiple Myeloma: Learnings from 2023
Current and Future Perspectives for Bispecific Antibodies in Multiple Myeloma: Learnings from 2023